Preclinical and translational strategy
Dr Sandeep Dhall
Dr Sandeep Dhall is a translational research leader with over a decade of experience advancing innovative therapies across gene therapy, biologics, and regenerative medicine.
COBS Prevention Trust funds research to correct the underlying cause of inherited cancer risk, so young asymptomatic adults no longer have to remove breasts and stomachs.
Today, people born with a faulty CDH1 gene are often advised to remove their stomach or their breasts in their twenties. The organ is functioning normally. The surgery creates permanent inadequate food metabolism and for many people longer-term mental or physical health challenges. Our vision is to make that removal choice unnecessary.
The CDH1 gene makes a protein called E-cadherin. E-cadherin holds billions of cells together. When the gene fails, cells lose their grip and drift out of place. That is how these cancers begin.
Our strategy has three parts.
We identify work like prime and base editors that could permanently restore normal CDH1 function. We approach institutes directly and we run open funding calls.
We award grants. We also collaborate on research directly where working alongside a team would achieve more than funding alone.
We publish what we learn. Drug developers, regulators, and families all need the same evidence base.
How clear is the website to here?
We are a grant-making charity. We find promising research, fund it, and drive medical advances.
Our Scientific Advisory Board reviews every proposal. Our trustees are responsible for the decisions. We meet quarterly.
We do not give medical advice and we do not provide treatment. If you need support or information about your own care, your doctor/physician and the organisations below are the right place to start.
Young adult, asymptomatic CDH1 carriers face a stark choice: surgically remove organs, or watch and wait through surveillance that cannot systematically tell the difference between early and advanced cancer. Both manage risk; neither corrects its source — which is precisely the gap a gene therapy could close to prevent advanced cancer.
The National Comprehensive Cancer Network® (NCCN®) states it is the recognised standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer V.1.2026 (opens in a new tab) show the gap and unmet medical need to test genetic medicine (Table 1).
In Table 1, the ‘emerging data’ for surveillance come from studies with follow-up typically under 10 years.
Table 1. NCCN pros and cons of current gastric cancer risk-management options
Adapted with permission from the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer V.1.2026. © 2026 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. (opens in a new tab) The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
The cost of the surgery is also well documented. A 2025 literature review (opens in a new tab) found that postoperative adjustment was substantial for many patients and could prevent them from returning fully to their preoperative lifestyle, including work, socialising, intimacy, reproduction and other daily-living activities.
Family cancer history can substantially increase individual risk estimates.
1Estimated cumulative risk for diagnosis through age 80. Referenced with permission from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer V.1.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 29, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org (opens in a new tab). NCCN makes no warranties of any kind whatsoever regarding its content, use or application and disclaims any responsibility for its application or use in any way.
How clear is why this research matters?
The awarded grants are clinically relevant: aligned with what regulators (FDA/MHRA) accept.
Developing an approved therapy requires more than one milestone (opens in a new tab). Considering the patients as central in public health, we fund research including disease models, natural history, delivery, safety, biomarkers, manufacturing, and regulatory translation. Our trustees and Scientific Advisory Board ensure sound governance, scientific rigour, ethical standards, and regulatory compliance. No grant is awarded without independent scientific review, and funding decisions on each proposal are made only by people who have no involvement in that proposal.
All areas below are subject to approval by our grant process, including review by our Scientific Advisory Board and trustees.
This is the hardest problem and the biggest prize. The stomach lining is not one target but millions of separate glands spread across a large internal surface. Reaching a few is not enough. A preventive therapy has to reach enough of the stem cells that renew the lining, across the whole organ, safely and effectively.
Solving delivery at this scale could advance far more than one disease.
How clear is the research we aim to fund?
We rely on funders to provide the funding we award as grants for cancer-prevention research.
An international board covering gastrointestinal oncology, lobular breast cancer, gene therapy, and translational development.
Preclinical and translational strategy
Dr Sandeep Dhall is a translational research leader with over a decade of experience advancing innovative therapies across gene therapy, biologics, and regenerative medicine.
Gene editing, genetics, and translational strategy
Dr Shiva Nickaria is a clinical translational scientist with expertise spanning genetics, immuno-oncology, rare-disease diagnostics, governance, and regulatory strategy.
Gastrointestinal oncology
Dr Adam Bass is a gastrointestinal medical oncologist and physician-scientist whose work connects cancer genomics with clinical care.
E-cadherin (CDH1 gene) and lobular breast cancer biology
Professor Patrick Derksen is a cancer biologist specialising in E-cadherin loss, invasive lobular breast cancer, and preclinical disease modelling.
Gavin studied molecular genetics, with a focus on the universal polymer deoxyribonucleic acid (DNA), including its synthesis, variants, and role in heredity. He founded Helionex, a gene-therapy research unit on his family's CDH1 sequence, and founded Cancers of the Breast and Stomach Prevention Trust for global public health.
Dr Hassan Elsaid is a postdoctoral research fellow at the University of Bergen / Haukeland University Hospital, Norway, where he studies tumour-stroma interactions and treatment response in head and neck squamous-cell carcinoma. Dr Elsaid's experience spans genetic-disease modelling, preclinical ethics, and research strategy.
James Chambers, PhD, is a professor at Tufts University School of Medicine and an investigator at Tufts Medical Center, Boston, MA. He examines how US health plans make coverage decisions for specialty drugs for rare and common diseases and how those decisions affect patient access.
Ayisha Sharma is the Trust’s Scientific Communications Administrator, supporting internal communications and leading external communications, including grant communications from initial enquiries through to final reports. She is also a biotechnology journalist at Financial Times' Endpoints News, covering cancer drug development, biotechnology and pharmaceutical science.
Ayisha Sharma is a science communicator and journalist with over five years of experience writing about medical breakthroughs. Ayisha is a news reporter for the Financial Times’ publication Endpoints News, which covers global biotechnology and pharmaceutical science, people, companies and the money that drives innovation. Endpoints reaches over 170,000 specialists daily. She has covered the full spectrum of cancer drug development, from early-stage clinical trial readouts to new drug approvals, and her other bylines include Citeline’s Scrip, GlobalData and The Observer. Ayisha supports our internal communications. She also leads our external communications, including for grants from initial enquiries through to final reports. Ayisha holds a BA in English and Philosophy from the University of Nottingham, UK, a News Associates diploma in Multimedia Journalism and an MA in Philosophy from University College London. Connect on LinkedIn (opens in a new tab).
No. Our goal is to support the research needed to develop an approved therapy. It is not a treatment available now to patients. We will always say clearly what is established and what is still a hypothesis.
Yes. Gene therapy has moved from the laboratory into patients. In 2026, it was reported that tailored genetic medicines had been used to treat more than 200 people across a range of rare diseases. Furthermore, the American Society of Gene and Cell Therapy’s Quarterly Landscape Report 2026 Q2 (opens in a new tab) reported over 2,000 gene therapies in the pipeline: over 1,000 are being developed for rare diseases. Over the last several years, the FDA (opens in a new tab) has reorganised for gene therapy (opens in a new tab) products. In 2026, the Broad Institute of MIT and Harvard announced a new architecture for genetic medicine, developed in collaboration with Boston Children’s Hospital and The Jackson Laboratory, to help make FDA-approved genetic medicine accessible through the Center for Therapeutic Genetics (opens in a new tab).
FDA approval of medicines requires highly regulated US oversight and transparency in preclinical testing of safety and efficacy before gene and cell therapies can be used in humans. In the UK, this regulatory oversight is provided by the Medicines and Healthcare products Regulatory Agency, and the European Commission oversees the approval of medicines in the European Union.
There is no approved chemoprevention medicine for hereditary diffuse gastric cancer. Medicines can reduce breast-cancer risk in a very low per cent of medium- and high-risk women, but they do not remove the need for better preventive options.
Entinostat is one experimental candidate. In preclinical studies, it inhibited growth in CDH1-null cells and mouse-derived (opens in a new tab) organoids. Researchers proposed that entinostat might both increase E-cadherin expression and normalise morphology in cells retaining one functional CDH1 copy while preferentially inhibiting growth, partly through apoptosis, in cells that had lost both copies. However, this remains a hypothesis. The breast experiments used MCF10A cells, which do not model the ER+ cells or luminal A (opens in a new tab) tumours typical of CDH1-associated breast cancer. More representative or patient-derived models may therefore be needed. Clinical trials of entinostat in other cancers have produced mixed results and substantial toxicity.
Clinical trials of entinostat in other cancers have produced mixed results and substantial toxicity. In a predominantly US-based phase 3 breast-cancer trial (80% White, 15% Black), entinostat plus exemestane did not meet its co-primary endpoints of progression-free survival (PFS) and overall survival (OS), and adverse events caused treatment discontinuation (opens in a new tab) in 16% of participants, compared with 8% receiving placebo. In a Chinese-patient phase 3 trial, the same combination improved median PFS by 2.6 months (HR, 0.76; 95% confidence interval (CI), 0.58–0.98; P=.046). The median OS was 38 months with entinostat and 29 months with placebo, a difference of 9 months. The study authors described this as clinically meaningful, although the adjusted OS comparison was not statistically significant (hazard ratio 0.78, 95% CI 0.58–1.05; P=.097) (opens in a new tab). Grade ≥3 (severe-or-worse) adverse events occurred in 66% of participants receiving entinostat, compared with 19% receiving placebo. In a phase 2 pancreatic metastatic cancer trial, Grade ≥3 treatment-related adverse events affected 63% of patients taking entinostat with nivolumab; 95% of those affected patients were attributed to entinostat; the primary endpoint was not met (opens in a new tab). These trials assessed treatment of established cancer, not cancer prevention.
A July 2026 phase 2 result using curcumin (Meriva) to treat H. pylori–negative gastric premalignant conditions (opens in a new tab) showed a significant reduction in gastric mucosal IL1β levels (P = 0.032). The trial did not demonstrate improved gastric histology so its relevance for CDH1-related chemoprevention is unclear.
For breast cancer, tamoxifen and other drugs are used. National Institute for Health and Care Excellence publishes clinical guidelines. Taking a medicine to reduce the chance of developing breast cancer [2017, updated November 2023] showed drugs including tamoxifen are selected according to menopausal status and can reduce the risk of developing breast cancer by approximately 0.7% to 3% (opens in a new tab) compared with no medicine. Those percentages are for women at high risk who take the medicine daily for five years. Depending on the medicine, the benefit may persist for at least 2-11 years after treatment. However, at the time of writing, the guidelines state the medicines have not been shown to reduce a patient's risk of dying from breast cancer.
Chemoprevention remains an important area of research. At present, however, chemoprevention medicine is not established for preventing hereditary diffuse gastric cancer or for CDH1-associated lobular breast cancer.
Chemotherapy and radiotherapy treat cancer once it has started. They can produce remission, but the cancer may recur. They do not prevent cancer. Diffuse gastric cancer is often found late when outcomes are poor.
These treatments are critical for cancer patients. We are working towards an option that means far fewer people need them.
Gene therapy is a broad category. We are particularly interested in base and prime editors, which are currently in multiple US clinical trials, some at an advanced stage. Base and prime editors restore the DNA sequence to ameliorate the underlying cause of genetic disease. The US trials provide an FDA-regulated foundation for treating rare-disease populations. To use these for CDH1, we award grants to develop the major milestone opportunities listed above in Research Priorities. Trials searched by intervention and disease can be found at clinicaltrials.gov (opens in a new tab), Be Part of Research (opens in a new tab), and connect.careboxhealth.com (opens in a new tab). The CDH1 research we aim to fund is intended to generate the evidence and capabilities needed for an approved therapy.
Surveillance does not prevent cancer. At best, it may detect cancer early and improve the chances of effective treatment. The EMBRACE investigators, supported by Cancer Research UK among others, are studying carriers with faulty breast cancer genes in the hope to determine what other factors may cause cancer development, whether cancer risk can be reduced, and whether early familial cancers can be detected through blood biopsies. CDH1 is included. At the time of writing, EMBRACE recruitment ends on 31 January 2027 (opens in a new tab).
Breast cancer detection in general is improving. Artificial intelligence (AI)-enhanced mammography showed improved breast-cancer-detection rates. The FDA cleared (opens in a new tab) some of these AIs, but at the time of writing, these latest breast-cancer AIs are not available in all centres. It is not clear how applicable these breast-cancer AIs are for lobular breast cancer. To our knowledge, there are no FDA-cleared recent AIs for better gastric cancer detection.
Yes. On registration, the charity will be legally, financially, and operationally independent and registered with the Charity Commission for public health. The charity is not controlled by, owned by, financially dependent on, or acting on behalf of another company, research group, university, commercial venture, or individual interest. Its decisions, finances, and activities belong to the charity itself. The trustees are legally responsible for ensuring the charity is for public benefit.
We are preparing to incorporate with the UK Charity Commission. Our Trustee and Scientific Advisory Boards are in place.
After incorporation, we will launch a crowdfunding campaign with an initial goal of £1.25 million to begin supporting research worldwide through the research priorities set out above.
How clear were the questions and answers?
We are recruiting Trustees through Reach Volunteering. Trustee roles are unpaid. However, the costs that trustees reasonably incur to perform their roles will be paid.
We welcome contact from researchers, funders, clinicians, and media.
Email: info@cobspreventiontrust.org